Towards a scoring system to distinguish early parkinsonian variant of multiple system atrophy from Parkinson’s disease
Objective: To develop a clinical score to distinguish between the parkinsonian variant of multiple system atrophy (MSA-P) and Parkinson’s disease (PD). Background: The differential diagnosis…Disease stage and UMSARS progression: Implications for clinical trials
Objective: To study the rate of progression of multiple system atrophy (MSA) and assess for a potential ceiling effect of the Unified Multiple System Atrophy…Electrochemical skin conductance as a marker of autonomic failure in patients with Multiple System Atrophy
Objective: We investigated the interest of a quick and non-invasive assessment of sweating as a marker of autonomic failure (AF) in Multiple System Atrohpy (MSA).…Relationship between REM sleep without atonia and sleep architecture in multiple system atrophy
Objective: To investigate whether REM sleep without atonia (RWA) is associated with sleep architecture in patients with multiple system atrophy (MSA). Background: In MSA patients,…Treatment of Neurogenic Orthostatic Hypotension (nOH) in Multiple System Atrophy (MSA) with a wearable Pneumatic Compression Garment utilising Soft Robotics
Objective: To use a novel Pneumatic Garment device for treatment of nOH in MSA. Background: nOH is present in 66-90% of patients with MSA and…Atypical Psychogenic Nonepileptic Seizure (PNES) preceding Multiple System Atrophy (MSA)
Objective: To share a case report of Atypical PNES and MSA. Background: Multiple system atrophy (MSA) is a rare neurodegenerative diagnosis that clinically presents with…Clinical profile and cerebral metabolic characteristic of cognitive impairments in multiple system atrophy
Objective: This study aimed to characterize the cognitive profiles of multiple system atrophy (MSA) and explore the possible mechanisms involved using 18F-fluorodeoxyglucose (FDG) Positron Emission…Quantitative evaluation of Multiple System Atorphy by triaxial accelerometers and 9-hole peg test
Objective: We need a concise and responsive biomarker for multiple system atrophy (MSA). Background: In Japan, the majority of patients of MSA are of the…Cardiac Safety of PBT434, an Inhibitor of Alpha-Synuclein Aggregation for the Treatment of Multiple System Atrophy (MSA)
Objective: Evaluate potential cardiac liability of PBT434 using concentration-response and outlier analyses of ECG and pharmacokinetic (PK) data from a Phase 1 study of PBT434…GCI-induced neurodegeneration and synucleinopathy in non-human primates
Objective: This study aimed at determining the potential to induce MSA pathology in non-human primates. Background: Aggregation of alpha-synuclein has been implicated in several neurodegenerative…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.